scholarly journals TREATMENT OF NON-SMALL CELL LUNG CANCER WITH ATEZOLIZUMAB: A CASE SERIES STUDY

Respirology ◽  
2018 ◽  
Vol 23 ◽  
pp. 296-297
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Case Series ◽  
Small Cell ◽  
Small Cell Lung ◽  
Case Series Study ◽  
Series Study

Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients

2013 ◽  
Vol 100 (12) ◽  
pp. E30-E37 ◽  
Author(s):  
Sylvestre Le Moulec ◽  
Julien Hadoux ◽  
Éric Gontier ◽  
Cyrus Chargari ◽  
Carole Helissey ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Case Series ◽  
Small Cell ◽  
Small Cell Lung ◽  
Case Series Study ◽  
Nsclc Patients ◽  
Series Study

scholarly journals Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series

2019 ◽  
Vol Volume 12 ◽  
pp. 7785-7790 ◽  
Author(s):  
Huiying Li ◽  
Tingting Yu ◽  
Mingmin Huang ◽  
Aibin Guo ◽  
Xiaoping Qian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Response ◽  
Cell Lung Cancer ◽  
Case Series ◽  
Small Cell ◽  
Leptomeningeal Metastases ◽  
Small Cell Lung

scholarly journals Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Nagla Abdel Karim ◽  
Ananta Bhatt ◽  
Lauren Chiec ◽  
Richard Curry
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Chemotherapy ◽  
Case Series ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Lung Cancer Patients

Lung cancer is the most common cause of cancer related mortality in men and women. Approximately 15% of lung cancers are small cell type. Chemotherapy and radiation are the mainstay treatments. Currently, the standard chemotherapy regimen includes platinum/etoposide. For extensive small cell lung cancer, irinotecan and cisplatin have also been used. Patients with relapsed small cell lung cancer have a very poor prognosis, and the morbidity increases with brain metastases. Approximately 10%–14% of small cell lung cancer patients exhibit brain metastases at the time of diagnosis, which increases to 50%–80% as the disease progresses. Mean survival with brain metastases is reported to be less than six months, thus calling for improved regimens. Here we present a case series of patients treated with irinotecan for progressive brain metastases in small cell lung cancer, which serves as a reminder of the role of systemic chemotherapy in this setting.

Sign in / Sign up

Export Citation Format

Share Document